Defects in lymphocyte subsets and serological memory persist a median of 10 years after high-dose therapy and autologous progenitor cell rescue for malignant lymphoma

Bone Marrow Transplantation
H F DeanA J Davies

Abstract

The number of survivors having undergone high-dose therapy (HDT) followed by auto-SCT continues to increase, although some of the long-term sequelae remain incompletely understood. The immunological status and quality of life of 37 HDT/auto-SCT survivors with lymphoma in continuous remission of ≥3 years were assessed alongside 14 age-matched controls. At a median follow-up of 10.5 years (range 2.2-20.2) following HDT/auto-SCT, the proportion of CD4(+) cells remained significantly reduced in patients compared with controls (median 43.4% vs 62.5%, respectively; P = < 0.001), predominantly a result of sustained reduction in the naive CD4(+) component (P < 0.001). Naive CD8(+) lymphocytes (P = 0.014) and transitional B cells (P = 0.008) were also significantly reduced, but differences in other lymphocyte subsets were not observed. Uptake of revaccination following HDT/auto-SCT was sporadic; between 11% and 33% of patients had serological titres outside the protective ranges for five of six routinely used vaccines. In the main, patients were found to have a good quality of life, although their EORTC QLQ-C30 questionnaire scores were significantly lower for the physical and social functioning domains compared with controls. Ten years...Continue Reading

References

Apr 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·K PauksenB Simonsson
Jul 1, 1993·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·V HammarströmP Ljungman
Jul 25, 1998·Bone Marrow Transplantation·V HammarströmP Ljungman
Oct 12, 1999·Bone Marrow Transplantation·T NordøyA Husebekk
Aug 31, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A RavaudUNKNOWN EORTC-ECSG
Jun 21, 2002·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·G KemmlerB Sperner-Unterweger
Oct 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry C SchoutenGunnar Kvalheim
May 20, 2004·JAMA : the Journal of the American Medical Association·Karen L SyrjalaPaul J Martin
Mar 8, 2005·Bone Marrow Transplantation·P LjungmanUNKNOWN Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.